Technical Analysis for NVAX - Novavax, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| See historical NVAX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | Fell Below 20 DMA | Bearish | 0.00% |
| Jan 18 | 50 DMA Support | Bullish | 0.00% |
| Jan 18 | Wide Bands | Range Expansion | 0.00% |
| Jan 17 | Narrow Range Bar | Range Contraction | -2.38% |
| Jan 17 | NR7 | Range Contraction | -2.38% |
| Jan 17 | Wide Bands | Range Expansion | -2.38% |
| Jan 16 | MACD Bearish Signal Line Cross | Bearish | -1.91% |
| Jan 16 | Narrow Range Bar | Range Contraction | -1.91% |
| Jan 16 | Wide Bands | Range Expansion | -1.91% |
| Jan 15 | Crossed Above 20 DMA | Bullish | -3.30% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-07
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more NVAX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 2.75 |
| 52 Week Low | 1.15 |
| Average Volume | 8,757,463 |
| 200-Day Moving Average | 1.7012 |
| 50-Day Moving Average | 2.0044 |
| 20-Day Moving Average | 2.0545 |
| 10-Day Moving Average | 2.17 |
| Average True Range | 0.1467 |
| ADX | 13.85 |
| +DI | 18.6885 |
| -DI | 20.1976 |
| Chandelier Exit (Long, 3 ATRs ) | 1.9299 |
| Chandelier Exit (Short, 3 ATRs ) | 2.1401 |
| Upper Bollinger Band | 2.3639 |
| Lower Bollinger Band | 1.7451 |
| Percent B (%b) | 0.49 |
| BandWidth | 30.11925 |
| MACD Line | 0.026 |
| MACD Signal Line | 0.037 |
| MACD Histogram | -0.0111 |
| Fundamentals | Value |
|---|---|
| Market Cap | 594.29 Million |
| Num Shares | 290 Million |
| EPS | -0.77 |
| Price-to-Earnings (P/E) Ratio | -2.66 |
| Price-to-Sales | 13.78 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.23 | ||||
| Resistance 3 (R3) | 2.23 | 2.18 | 2.20 | ||
| Resistance 2 (R2) | 2.18 | 2.13 | 2.18 | 2.19 | |
| Resistance 1 (R1) | 2.11 | 2.10 | 2.09 | 2.11 | 2.18 |
| Pivot Point | 2.06 | 2.06 | 2.04 | 2.06 | 2.06 |
| Support 1 (S1) | 1.99 | 2.01 | 1.97 | 1.99 | 1.92 |
| Support 2 (S2) | 1.94 | 1.98 | 1.94 | 1.91 | |
| Support 3 (S3) | 1.87 | 1.94 | 1.90 | ||
| Support 4 (S4) | 1.87 |
